Sjögren's disease trials in Italy

In Italy 10 Also abroad 80

10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Where
Cuneo, Pisa, Rome, Rozzano, Udine
Age
18 years and over
People
570 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07621809 · EU 2025-522271-29-00
Phase 2Taking people
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Where
Rome, Rozzano, Udine
Age
18 years to 100 years
People
344 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07737743 · EU 2025-524513-92-00
Phase 3Taking people
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Where
Ancona, Milan, Rome, Rozzano
Age
18 years to 75 years
People
250 worldwide
Run by
Vor Biopharma
See details and how to joinNCT07404865 · EU 2026-525556-28-00
Phase 2Not yet taking people in Italy
A randomized, parallel-group, open-label, Phase IIb pilot trial to evaluate the effectiveness in reducing systemic disease activity with methotrexate compared with hydroxychloroquine in adult male and female participants with moderate-to-severe primary Sjögren’s disease (MOSAIC STUDY)
Where
Pescara, Rome, Turin
Age
18 years and over
People
70
Run by
Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata Fon
See details and how to join2026-526767-38-00 · EU 2026-526767-38-00
Phase 1Taking people
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Where
Roma
Age
18 years and over
People
36 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to joinNCT07041099
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Brescia, Milan, Rome
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Ferrara, Rozzano
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 1Taking people
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease
Where
Naples, Rome
Age
18 years and over
People
40 worldwide
Run by
Cullinan Therapeutics Inc.
See details and how to join2025-521462-96-00 · EU 2025-521462-96-00
Phase 3Taking people
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Where
Catania, Florence, Milan, Pisa, Reggio Emilia, Rome, Turin, Udine, Verona
Age
18 years and over
People
844 worldwide
Run by
Amgen
See details and how to joinNCT06747949 · EU 2024-517513-32-00
No phaseTaking people
Ultra-High Frequency Ultrasonography in Sjögren's Syndrome
Where
Pisa
Age
18 years and over
People
800
Run by
University of Pisa
See details and how to joinNCT06338735